Michael Hoffmeister1, Lina Jansen2, Anja Rudolph2, Csaba Toth2, Matthias Kloor2, Wilfried Roth2, Hendrik Bläker2, Jenny Chang-Claude2, Hermann Brenner2. 1. Division of Clinical Epidemiology and Aging Research (MH, LJ, HBr), Division of Cancer Epidemiology (AR, JCC), and Unit of Molecular Tumor Pathology (WR), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pathology (CT, WR) and Department of Applied Tumor Biology (MK), Institute of Pathology, Heidelberg University Hospital, Germany; Institute of Pathology, Charité University Medicine, Berlin, Germany (HBl); German Cancer Consortium (DKTK), Heidelberg, Germany (HBr). m.hoffmeister@dkfz.de. 2. Division of Clinical Epidemiology and Aging Research (MH, LJ, HBr), Division of Cancer Epidemiology (AR, JCC), and Unit of Molecular Tumor Pathology (WR), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pathology (CT, WR) and Department of Applied Tumor Biology (MK), Institute of Pathology, Heidelberg University Hospital, Germany; Institute of Pathology, Charité University Medicine, Berlin, Germany (HBl); German Cancer Consortium (DKTK), Heidelberg, Germany (HBr).
Abstract
BACKGROUND: Statins have been associated with moderate reductions in mortality among colorectal cancer (CRC) patients, but these studies lacked adjustment for some potentially relevant factors associated with statin use. We aimed to provide more detailed results on this association from a population-based patient cohort study. METHODS: Use of statins and other risk or protective factors were assessed in standardized interviews with 2697 patients from southern Germany with a diagnosis of incident CRC between 2003 and 2009 (Darmkrebs: Chancen der Verhütung durch Screening [DACHS] study). Follow-up included assessment of therapy details, recurrence, vital status, and cause of death. Information about molecular pathological subtypes of CRC was available for 1209 patients. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: Patients were age 68 years on average, 412 used statins (15%), and 769 died during follow-up (29%). After a median follow-up time of 3.4 years, use of statins was not associated with overall (HR = 1.10, 95% CI = 0.85 to 1.41), CRC-specific (HR = 1.11, 95% CI = 0.82 to 1.50), or recurrence-free survival (HR = 0.90, 95% CI = 0.63 to 1.27). Analyses in relevant subgroups also showed no association of statin use with overall and CRC-specific survival, and no associations were observed after stratifying for major pathological subtypes. Among stage I and II patients, statin use was associated with better recurrence-free but not with better CRC-specific survival. CONCLUSIONS: Statin use was not associated with reduced mortality among CRC patients. Effects reported in previous studies might reflect incomplete control for stage at diagnosis and other factors associated with the use of statins.
BACKGROUND: Statins have been associated with moderate reductions in mortality among colorectal cancer (CRC) patients, but these studies lacked adjustment for some potentially relevant factors associated with statin use. We aimed to provide more detailed results on this association from a population-based patient cohort study. METHODS: Use of statins and other risk or protective factors were assessed in standardized interviews with 2697 patients from southern Germany with a diagnosis of incident CRC between 2003 and 2009 (Darmkrebs: Chancen der Verhütung durch Screening [DACHS] study). Follow-up included assessment of therapy details, recurrence, vital status, and cause of death. Information about molecular pathological subtypes of CRC was available for 1209 patients. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS:Patients were age 68 years on average, 412 used statins (15%), and 769 died during follow-up (29%). After a median follow-up time of 3.4 years, use of statins was not associated with overall (HR = 1.10, 95% CI = 0.85 to 1.41), CRC-specific (HR = 1.11, 95% CI = 0.82 to 1.50), or recurrence-free survival (HR = 0.90, 95% CI = 0.63 to 1.27). Analyses in relevant subgroups also showed no association of statin use with overall and CRC-specific survival, and no associations were observed after stratifying for major pathological subtypes. Among stage I and II patients, statin use was associated with better recurrence-free but not with better CRC-specific survival. CONCLUSIONS: Statin use was not associated with reduced mortality among CRC patients. Effects reported in previous studies might reflect incomplete control for stage at diagnosis and other factors associated with the use of statins.
Authors: Prudence R Carr; Barbara L Banbury; Sonja I Berndt; Peter T Campbell; Jenny Chang-Claude; Richard B Hayes; Barbara V Howard; Lina Jansen; Eric J Jacobs; Dorothy S Lane; Reiko Nishihara; Shuji Ogino; Amanda I Phipps; Martha L Slattery; Marcia L Stefanick; Robert Wallace; Viola Walter; Emily White; Kana Wu; Ulrike Peters; Andrew T Chan; Polly A Newcomb; Hermann Brenner; Michael Hoffmeister Journal: Clin Gastroenterol Hepatol Date: 2018-11-23 Impact factor: 11.382
Authors: Sherif M El-Refai; Joshua D Brown; Susanne M Arnold; Esther P Black; Markos Leggas; Jeffery C Talbert Journal: JCO Clin Cancer Inform Date: 2017-11
Authors: Sonja Neumeyer; Katja Butterbach; Barbara L Banbury; Sonja I Berndt; Peter T Campbell; Rowan T Chlebowski; Andrew T Chan; Edward L Giovannucci; Amit D Joshi; Shuji Ogino; Mingyang Song; Marjorie L McCullough; Haifa Maalmi; JoAnn E Manson; Lori C Sakoda; Robert E Schoen; Martha L Slattery; Emily White; Aung K Win; Jane C Figueiredo; John L Hopper; Finlay A Macrae; Ulrike Peters; Hermann Brenner; Michael Hoffmeister; Polly A Newcomb; Jenny Chang-Claude Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-03-18 Impact factor: 4.254
Authors: Louise Emilsson; Xabier García-Albéniz; Roger W Logan; Ellen C Caniglia; Mette Kalager; Miguel A Hernán Journal: JAMA Oncol Date: 2018-01-01 Impact factor: 31.777
Authors: Alexander T Pearson; Tom Luedde; Jakob Nikolas Kather; Lara R Heij; Heike I Grabsch; Chiara Loeffler; Amelie Echle; Hannah Sophie Muti; Jeremias Krause; Jan M Niehues; Kai A J Sommer; Peter Bankhead; Loes F S Kooreman; Jefree J Schulte; Nicole A Cipriani; Roman D Buelow; Peter Boor; Nadi-Na Ortiz-Brüchle; Andrew M Hanby; Valerie Speirs; Sara Kochanny; Akash Patnaik; Andrew Srisuwananukorn; Hermann Brenner; Michael Hoffmeister; Piet A van den Brandt; Dirk Jäger; Christian Trautwein Journal: Nat Cancer Date: 2020-07-27
Authors: Amanda I Phipps; Elizabeth Alwers; Tabitha Harrison; Barbara Banbury; Hermann Brenner; Peter T Campbell; Jenny Chang-Claude; Daniel Buchanan; Andrew T Chan; Alton B Farris; Jane C Figueiredo; Steven Gallinger; Graham G Giles; Mark Jenkins; Roger L Milne; Polly A Newcomb; Martha L Slattery; Mingyang Song; Shuji Ogino; Syed H Zaidi; Michael Hoffmeister; Ulrike Peters Journal: Gastroenterology Date: 2020-02-20 Impact factor: 22.682